Company Description
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specia...
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Valuation
P/E Current
17.50
P/E Ratio (with extraordinary items)
16.39
P/E Ratio (without extraordinary items)
17.83
Price to Sales Ratio
2.95
Price to Book Ratio
1.62
Price to Cash Flow Ratio
10.59
Enterprise Value to EBITDA
10.25
Enterprise Value to Sales
3.01
Total Debt to Enterprise Value
0.18
Efficiency
Revenue/Employee
395,643.00
Income Per Employee
65,202.00
Receivables Turnover
3.83
Total Asset Turnover
0.32
Liquidity
Current Ratio
1.44
Quick Ratio
1.03
Cash Ratio
0.47
Profitability
Gross Margin
63.07
Operating Margin
22.95
Pretax Margin
20.65
Net Margin
16.48
Return on Assets
5.30
Return on Equity
9.45
Return on Total Capital
9.72
Return on Invested Capital
7.26
Capital Structure
Total Debt to Total Equity
32.63
Total Debt to Total Capital
24.61
Total Debt to Total Assets
18.64
Long-Term Debt to Equity
27.61
Long-Term Debt to Total Capital
20.82
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Serge Weinberg | 70 | 2009 | Director |
Mr. Paul Hudson | 53 | 2019 | Chief Executive Officer |
Mr. Jean-Baptiste Chasseloup de Chatillon | 56 | 2018 | Chief Financial Officer & Executive Vice President |
Dr. Dietmar P. Berger | - | - | Chief Medical Officer & Global Head-Development |
Dr. John C. Reed | 61 | 2018 | EVP & Global Head-Research & Development |
Insider Actions
12/22/2021 |
Barbara Lavernos |
500 | Acquisition at $87.7 per share. | 43,850 |
12/22/2021 |
Barbara Lavernos |
500 | Acquisition at $87.7 per share. | 43,850 |
11/18/2020 |
Rachel Duan |
601 | Acquisition at $85.63 per share. | 51,463 |
11/18/2020 |
Rachel Duan |
132 | Acquisition at $85.62 per share. | 11,301 |
11/18/2020 |
Rachel Duan |
267 | Acquisition at $85.5 per share. | 22,828 |
11/12/2020 |
Lise Kingo |
1,000 | Acquisition at $85.2 per share. | 85,204 |
02/21/2020 |
Sanofi |
96,700 | Acquisition at $93.07 per share. | 8,999,665 |
02/20/2020 |
Sanofi |
84,000 | Acquisition at $93.78 per share. | 7,877,830 |
02/19/2020 |
Sanofi |
60,000 | Acquisition at $94.29 per share. | 5,657,406 |
02/18/2020 |
Sanofi |
27,700 | Acquisition at $92.45 per share. | 2,560,809 |
02/17/2020 |
Sanofi |
27,500 | Acquisition at $92.2 per share. | 2,535,461 |
12/13/2019 |
Paul Hudson |
5,600 | Acquisition at $88.51 per share. | 495,656 |
12/13/2019 |
Paul Hudson |
5,600 | Acquisition at $88.51 per share. | 495,656 |
11/04/2019 |
Christophe Babule |
500 | Acquisition at $82.81 per share. | 41,405 |
11/04/2019 |
Christophe Babule |
500 | Acquisition at $82.81 per share. | 41,405 |
MarketWatch News on SNYNF
-
The New Doctor in the House: Consolidation
- Barrons.com
-
Your Money: Pros, cons of paying taxes with a credit card
- CBS.MarketWatch.com
-
Retail sales roar ahead in February
- CBS.MarketWatch.com
-
Clueless Investor: Web making muni bonds more accessible to individuals
- CBS.MarketWatch.com
-
Michael J. Bazdarich: No need to worry about the 'wealth effect'
- CBS.MarketWatch.com
-
Washington schedule for March 13-19
- CBS.MarketWatch.com
-
Joe Battipaglia: Economic data will show that inflation is tame
- CBS.MarketWatch.com
-
Washington schedule for March 13-19
- CBS.MarketWatch.com
Other News on SNYNF
-
Novo Nordisk: Looming Danger In An Excellent Business
- Seeking Alpha
-
GSK: Zantac Litigation Risks Have Been Ignored For Too Long
- Seeking Alpha
-
GSK, Sanofi in selloff extending Novavax-led rout
- Seeking Alpha
-
EWQ Has 'Made In France' Resilience On Offer
- Seeking Alpha
-
Sanofi: Arguably One Of The Most Undervalued Pharma Stocks
- Seeking Alpha
-
Sanofi 2022 Q2 - Results - Earnings Call Presentation
- Seeking Alpha
-
Seres Therapeutics: The Good And The Challenging
- Seeking Alpha
-
Wide-Moat Stocks On Sale - The July 2022 Heat Map
- Seeking Alpha
-
Healthcare Sector Stock Performance Continues To Improve
- Seeking Alpha
- Loading more headlines...